Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for JEMDELT1 (halobetasol propionate 0.01%) IDP-122 lotion. The PDUFA action date is set for October 5, 2018.
from RTT - Biotech http://ift.tt/2Cj239D
via IFTTT
No comments:
Post a Comment